Treatments Available for Surge of Alzheimer’s Cases

Treatments Available for Surge of Alzheimer’s Cases

Treatments Available for Surge of Alzheimers Cases
Anti-Alzheimer's, Antidimentia, Drug Research & Development API

The approval of Aricept fifteen years ago was the last time there was anything new to treat the symptoms of Alzheimer’s disease. This lack of research and drug development is unnerving to patients and practitioners alike, with this lethal disease affecting 5.4 million Americans. On June 13, 2013 the BCC posted an alarming research report, citing the lack of current R&D for Alzheimer’s disease to be leading the pharmaceutical arena into a dangerous territory. The exponential number of cases of Alzheimer’s is due to proliferate, especially due to the percentage of adults over 65 years of age due to grow worldwide over the next four decades. Alzheimer s disease is predicted to have more than double the cases, to an estimated 53 million adults worldwide by the year 2050.


There is hope, however, with the resources available for researchers to utilize current API’s to create viable solutions for this ever growing patient population. There are several products currently FDA approved and available. LGM Pharma provides these quality APIs, like Donepezil, Memantine and Bexarotene, to supply your R&D needs.


Donepezil, CAS# 120014-06-4, also known as the brand name Aricept, is an efficacious treatment for the symptoms of Alzheimer’s disease. Patients with Alzheimer’s have shown to have low levels of the brain chemical acetylcholine, which is a crucial chemical for thinking and memory issues. Donepezil improves the patient’s nerve cell functioning by inhibiting the breakdown of acetylcholine. Recent research regarding new drugs that are similar to donepezil was revealed at the Neuroscience Conference in South Australia on February 4, 2013. Bionomics Limited announced that new data on BNC375, its drug candidate with potential for the treatment of memory loss in Alzheimer’s Disease, would be explored as the next new Alzheimer’ drug. The performance of BNC375 in animal tests thus far matches donepezil results. BNC375, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor , has proven in a number of animal studies that it successfully enhances both episodic memory and working memory, and compares equivocally to the performance of donepezil {Aricept}.


MemantineMemantine, CAS number 41100-52-1, is another effective oral medication for treating patients with Alzheimer’s disease. Memantine is the first in a new and formidable class of Alzheimer’s drugs which work by blocking NMDA glutamate receptors. Known as its brand name Namenda, marketed in the United States by Forest Laboratories, Memantine is typically prescribed for the treatment of moderate to severe dementia associated with Alzheimer’s disease. On March 7, 2012 a study was released and published in the New England Journal of Medicine, which involved 295 Alzheimer’s patients in Britain who were given Memantine and donepezil. These patients were placed in one of four separate groups: patients continuing to take donepezil; patients stopping donepezil and receiving a placebo; patients stopping donepezil and starting Memantine; and patients taking both Memantine and donepezil together. The value of treating patients with mild to severe Alzheimer’s was found upon studying the effects of both Memantine and donepezil. The continuation of drug treatment, even in patients deemed severe, proved to be effectual and successful when compared to the placebo group in this study. Patients who received both Memantine and donepezil in this study fared significantly better, displaying worthier cognitive and functional abilities in comparison to the other study participants.


Bexarotene, CAS number 153559-49-0, has also been shown to be a potential opponent in the fight against Alzheimer’s disease. As of February 13th, 2012 Stacy Pagos Haller, President and CEO of the American Health Assistance Foundation, announced documented success in studies using Bexarotene. These studies demonstrated a distinct benefit to Bexarotene in clearing out the excess plaque found in the Alzheimer’s-disease brains of the mice studied. Bexarotene also effectively enhanced the body’s natural defense mechanisms, and helped to clear amyloid beta proteins, which is a naturally occurring protein in the brain that is unable to be cleared from the Alzheimer’s disease brain. LGM Pharma provides API Bexarotene, as well as Memantine and Donepezil for research and development purposes. Clients can be assured of continuous support throughout the R& D process, as well as quality API products.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service